Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
164 hedge funds and large institutions have $129M invested in Esperion Therapeutics in 2023 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 32 closing their positions.
134% more call options, than puts
Call options by funds: $5.08M | Put options by funds: $2.17M
45% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 44
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
1% less funds holding
Funds holding: 165 → 164 (-1)
8.62% less ownership
Funds ownership: 99.81% → 91.19% (-8.6%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
72% less capital invested
Capital invested by funds: $458M → $129M (-$329M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$33.6M |
| 2 |
AC
Armistice Capital
New York
|
+$19M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.55M |
| 4 |
Millennium Management
New York
|
+$7.48M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$24.9M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$11.3M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$4.72M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.19M |
| 5 |
ACM
Altium Capital Management
New York
|
-$3.86M |
ESPR Hedge Fund Activity: Q1 2023 in Review
164 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2023, worth a combined $129M — down 72% from $458M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ESPR positions and 32 closed out — a net gain of 1 holder — while 64 added to existing stakes and 44 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $33.6M. The largest seller was Deep Track Capital, exiting entirely with an estimated $24.9M sold.
- 164 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2023, down from 165 in Q4 2022.
- Funds reported $129M of Esperion Therapeutics stock for Q1 2023, down 72% quarter-over-quarter.
- 33 funds opened new Esperion Therapeutics positions in Q1 2023 and 32 closed out, a net change of +1 holder.
- The largest Esperion Therapeutics buyer in Q1 2023 was Wasatch Advisors, an estimated $33.6M added.
- The largest Esperion Therapeutics seller in Q1 2023 was Deep Track Capital, an estimated $24.9M sold.
Based on aggregated 13F filings for Q1 2023.